Prognostic Significance of Cyclin D1 Expression in Renal Cell Carcinoma: a Systematic Review and Meta-analysis
- 27 Downloads
Previous studies indicated that cyclin D1 shown the potential as a tumor biomarker. However, the prognostic value of cyclin D1 in renal cell carcinoma (RCC) remains controversial. This study investigated the correlation of cyclin D1 expression with the prognostic and clinicopathological features in RCC patients. We systematically searched the database of PubMed, Embase, Cochrane, and Web of Science updated on November 26, 2017. Eighteen studies with 2282 patients satisfied the inclusion criteria. Results demonstrated that cyclin D1 overexpression in RCC showed significant favorable prognostic impact on disease-free survival (DFS) (HR 0.57, 95% CI: 0.43–0.74) and disease-specific survival (DSS) (HR 0.59, 95% CI 0.41–0.85) without significant heterogeneity. In subgroup of clear cell RCC, the prognostic effect on DFS was robust and the pooled HR was 0.39 (95% CI: 0.27–0.57). However, no association between overall survival (OS) and cyclin D1 expression was observed. Stratified analysis in DFS studies by sample size, staining patterns race and metastasis status showed similar results. Otherwise, cyclin D1 overexpression predicted a reduced prevalence of high TNM stage (T3 + T4) (OR 0.63, 95% CI: 0.40–0.99), high-grade tumor (G3 + G4) (OR 0.51, 95% CI: 0.31–0.81) and large tumor size (OR 0.35, 95% CI: 0.19–0.62). Our meta-analysis indicated that cyclin D1 overexpression could predict the favorable prognosis in patients with RCC.
KeywordsCyclin D1 Renal cell carcinoma Prognosis Meta-analysis
We thank Dr. Lubomir Bodnar for providing the original data. This work was supported by grants of Science Foundation of Shandong Province (No.ZR2015HM046) and a grant of National Natural Science Foundation of China (81672522).
Compliance with Ethical Standards
This research does not involve Human Participants and/or Animals.
This article does not contain any studies with human participants performed by any of the authors. No informed consent is needed.
Conflict of Interest
The authors declare that they have no conflict of interest.
- 2.MacLennan S, Imamura M, Lapitan MC, Omar MI, Lam TB, Hilvano-Cabungcal AM, Royle P, Stewart F, MacLennan G, MacLennan SJ, Canfield SE, McClinton S, Griffiths TR, Ljungberg B, N’Dow J (2012) Systematic review of oncological outcomes following surgical management of localised renal cancer. Eur Urol 61(5):972–993. https://doi.org/10.1016/j.eururo.2012.02.039 CrossRefPubMedGoogle Scholar
- 7.Aaltomaa S, Lipponen P, Ala-Opas M, Eskelinen M, Syrjanen K, Kosma VM (1999) Expression of cyclins a and D and p21(waf1/cip1) proteins in renal cell cancer and their relation to clinicopathological variables and patient survival. Br J Cancer 80(12):2001–2007. https://doi.org/10.1038/sj.bjc.6690634 CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Ishii Y, Pirkmaier A, Alvarez JV, Frank DA, Keselman I, Logothetis D, Mandeli J, O’Connell MJ, Waxman S, Germain D (2006) Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model. J Natl Cancer Inst 98(17):1238–1247. https://doi.org/10.1093/jnci/djj334 CrossRefPubMedGoogle Scholar
- 16.Furukawa J, Miyake H, Fujisawa M (2016) GLI2 expression levels in radical nephrectomy specimens as a predictor of disease progression in patients with metastatic clear cell renal cell carcinoma following treatment with sunitinib. Mol Clin Oncol 5(3):186–192. https://doi.org/10.3892/mco.2016.950 CrossRefGoogle Scholar
- 18.Chaves Portela S, Santos-Arrontes D, Fernandez-Acenero MJ, Garcia Gonzalez J, Paniagua P (2011) Stage pT3a of renal clear cell carcinoma: do tumors with sinus fat involvement behave the same as those with perinephric fat involvement? Rom J Morphol Embryol = Revue Roumaine de Morphologie et EMBRYOLOGIE 52(2):569–574Google Scholar
- 20.Biswas S, Charlesworth PJ, Turner GD, Leek R, Thamboo PT, Campo L, Turley H, Dildey P, Protheroe A, Cranston D, Gatter KC, Pezzella F, Harris AL (2012) CD31 angiogenesis and combined expression of HIF-1alpha and HIF-2alpha are prognostic in primary clear-cell renal cell carcinoma (CC-RCC), but HIFalpha transcriptional products are not: implications for antiangiogenic trials and HIFalpha biomarker studies in primary CC-RCC. Carcinogenesis 33(9):1717–1725. https://doi.org/10.1093/carcin/bgs222 CrossRefPubMedGoogle Scholar
- 22.Allory Y, Matsuoka Y, Bazille C, Christensen EI, Ronco P, Debiec H (2005) The L1 cell adhesion molecule is induced in renal cancer cells and correlates with metastasis in clear cell carcinomas. Clin Cancer Res : an Official Journal of the American Association for Cancer Research 11(3):1190–1197Google Scholar
- 24.Kusuda Y, Miyake H, Behnsawy HM, Fukuhara T, Inoue TA, Fujisawa M (2013) Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens. Urol Oncol 31(1):42–50. https://doi.org/10.1016/j.urolonc.2010.09.008 CrossRefPubMedGoogle Scholar
- 25.Bodnar L, Stec R, Cierniak S, Synowiec A, Wcislo G, Jesiotr M, Koktysz R, Kozlowski W, Szczylik C (2015) Clinical usefulness of PI3K/Akt/mTOR genotyping in companion with other clinical variables in metastatic renal cell carcinoma patients treated with everolimus in the second and subsequent lines. Ann Oncol : OFFICIAL journal of the European Society for Medical Oncology 26(7):1385–1389. https://doi.org/10.1093/annonc/mdv166 CrossRefGoogle Scholar
- 26.Su T, Han Y, Yu Y, Tan X, Li X, Hou J, Du Y, Shen J, Wang G, Ma L, Jiang S, Zhang H, Cao G (2013) A GWAS-identified susceptibility locus on chromosome 11q13.3 and its putative molecular target for prediction of postoperative prognosis of human renal cell carcinoma. Oncol Lett 6(2):421–426. https://doi.org/10.3892/ol.2013.1422 CrossRefPubMedPubMedCentralGoogle Scholar
- 27.Dahinden C, Ingold B, Wild P, Boysen G, Luu VD, Montani M, Kristiansen G, Sulser T, Buhlmann P, Moch H, Schraml P (2010) Mining tissue microarray data to uncover combinations of biomarker expression patterns that improve intermediate staging and grading of clear cell renal cell cancer. Clin Cancer Res : an Official Journal of the American Association for Cancer Research 16(1):88–98. https://doi.org/10.1158/1078-0432.ccr-09-0260 CrossRefGoogle Scholar
- 28.Wang F, Guo CH, Sun W, Dong Y, Yang Z (2012) Expressions of E-cadherin, β-catenin and Cyclin D1 in renal clear cell carcinoma. Chinese Journal of Cancer Prevention and Treatment 19(22):1716–1718+1729Google Scholar
- 30.Ge JR, Ren GP, Yao HP (2007) Expression of cyclin D1 and p27kip1 in renal cell carcinoma and its significance. Zhejiang Da Xue Xue Bao Yi Xue Ban = Journal of Zhejiang University Medical sciences 36(5):483–487Google Scholar
- 32.Wells G (2004) The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis. Cancer. 2002 Feb 15;94(4):973-9. http://www.ohrica/programs/clinical_epidemiologyoxford.htm
- 33.Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283(15):2008–2012CrossRefGoogle Scholar
- 36.Jirawatnotai S, Hu Y, Michowski W, Elias JE, Becks L, Bienvenu F, Zagozdzon A, Goswami T, Wang YE, Clark AB, Kunkel TA, van Harn T, Xia B, Correll M, Quackenbush J, Livingston DM, Gygi SP, Sicinski P (2011) A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature 474(7350):230–234. https://doi.org/10.1038/nature10155 CrossRefPubMedPubMedCentralGoogle Scholar